Biosketch

A native of Minnesota, Dr. David Stroncek completed his undergraduate and medical school degrees, an internal medicine residency, and a hematology/oncology fellowship at the University of Minnesota. He then joined the faculty of the University of Minnesota Medical School, Laboratory Medicine and Pathology Department as associate medical director of the blood blank.

He helped establish the National Marrow Donor Program (NMDP) and was the organization’s first medical director. During his four years as medical director of the NMDP, the program coordinated their first unrelated donor transplant and subsequently increased the number of employees and marrow donations by unrelated individuals. He has served on several NMDP committees as president of the council of the NMDP and as a member of the NMDP board of directors.

Dr. Stroncek came to the NIH Clinical Center Department of Transfusion Medicine (DTM) in 1996 as chief of the Laboratory Service Section. In this role, he directed the HLA and Transfusion Services Laboratories.

During his tenure, the HLA laboratory moved from a serological laboratory to a molecular testing laboratory that provided sequence-specific probe, high resolution sequence-specific primer, and sequence-based HLA genotyping. The laboratory also began providing KIR genotyping to support hematopoietic stem cell transplant patients and histocompatibilty testing to support the Clinical Center’s unrelated marrow donor transplant program. Under Dr. Stroncek’s direction, the Transfusion Service Laboratory began genotyping RBC antigens and discovered that the low pH and high osmolarity of citrate anticoagulant in blood components caused RBCs from donors with sickle cell trait to occlude leukocyte reduction filters. The laboratory also investigated the contribution of leukocyte antibodies to transfusion reactions and advanced the understanding of the molecular basis of neutrophil-specific antigens.

Dr. Stroncek became chief of the Cell Processing Section in 2007. In this role, he is using gene and micro RNA expression profiling to improve potency and stability testing of cellular therapies. 

He has published more than 170 articles in scientific journals and has written several book chapters. He has served on the editorial boards of several scientific journals.

Selected Publications

JOURNAL REVIEWS

Stroncek DF. Neutrophil-specific antigen HNA-2a, NB1 glycoprotein, and CD177. Curr Opin Hematol. 2007 Nov;14(6):688-93.

Stroncek DF, Rebulla P. Platelet transfusions. Lancet. 2007 Aug 4;370(9585):427-38.

Stroncek DF, Jin P, Wang E, Jett B. Potency analysis of cellular therapies: the emerging role of molecular assays. J Transl Med. 2007 May 30;5:24.

Stroncek DF, Burns C, Martin BM, Rossi L, Marincola FM, Panelli MC. Advancing cancer biotherapy with proteomics. J Immunother. 2005 May-Jun;28(3):183-92.

Stroncek DF, Caruccio L, Bettinotti M. CD177: A member of the Ly-6 gene superfamily involved with neutrophil proliferation and polycythemia vera. J Transl Med. 2004 Mar 29;2(1):8.
 
Stroncek D, Harvath L, Barrett J. National Heart, Lung, and Blood Institute of the National Institutes of Health forum on immune reconstitution and cellular therapy following hematopoietic stem-cell transplantation. Cytotherapy. 2002;4(5):415-8.

Stroncek D. Neutrophil alloantigens. Transfus Med Rev. 2002 Jan;16(1):67-75.

JOURNAL ARTICLES

Fadeyi EA, De Los Angeles Muniz M, Wayne AS, Klein HG, Leitman SF, Stroncek DF. The transfusion of neutrophil-specific antibodies causes leukopenia and a broad spectrum of pulmonary reactions. Transfusion. 2007 Mar;47(3):545-50.

Lim JB, Provenzano M, Kwon OH, Bettinotti M, Caruccio L, Nagorsen D, Stroncek D. Identification of HLA-A33-restricted CMV pp65 epitopes as common targets for CD8(+) CMV-specific cytotoxic T lymphocytes. Exp Hematol. 2006 Mar;34(3):296-307.

Caruccio L, Bettinotti M, Director-Myska AE, Arthur DC, Stroncek D. The gene overexpressed in polycythemia rubra vera, PRV-1, and the gene encoding a neutrophil alloantigen, NB1, are alleles of a single gene, CD177, in chromosome band 19q13.31. Transfusion. 2006 Mar;46(3):441-7.

Stroncek DF, Rainer T, Sharon V, Byrne KM, Noguchi CT, Klein HG, Schechter AN, Leitman SF. Sickle Hb polymerization in RBC components from donors with sickle cell trait prevents effective WBC reduction by filtration. Transfusion. 2002 Nov;42(11):1466-72.

Stroncek DF, Clay ME, Petzoldt ML, Smith J, Jaszcz W, Oldham FB, McCullough J. Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion. 1996 Jul;36(7):601-10.

Stroncek DF, Holland PV, Bartch G, Bixby T, Simmons RG, Antin JH, Anderson KC, Ash RC, Bolwell BJ, Hansen JA, et al. Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program. Blood. 1993 Apr 1;81(7):1940-6.

Stroncek DF, Vercellotti GM, Hammerschmidt DE, Christie DJ, Shankar RA, Jacob HS. Characterization of multiple quinine-dependent antibodies in a patient with episodic hemolytic uremic syndrome and immune agranulocytosis. Blood. 1992 Jul 1;80(1):241-8.

Stroncek DF, Skubitz KM, Plachta LB, Shankar RA, Clay ME, Herman J, Fleit HB, McCullough J. Alloimmune neonatal neutropenia due to an antibody to the neutrophil Fc-gamma receptor III with maternal deficiency of CD16 antigen. Blood. 1991 Apr 1;77(7):1572-80.

Stroncek DF, Skubitz KM, McCullough J. Biochemical characterization of the neutrophil-specific antigen NB1.Blood. 1990 Feb 1;75(3):744-55.